// App-Quantinova.ai

: Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • William S. Chen

Principal Investigators

  • Li Zhang

  • Shuang Zhao

  • Tomasz M. Beer

  • David A Quigley

  • Adam Foye

  • Denise Playdle

  • Paul Lloyd

  • Matthew Rettig

  • Martin Gleave

  • Christopher P. Evans

  • Primo Lara

  • Vishal Kothari

  • Kim N. Chi

  • Robert Evan Reiter

  • Christopher Maher

  • Felix Y Feng

  • Eric Jay Small

  • Joshi J. Alumkal

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Michigan, Ann Arbor, MI

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • University of California, Davis Comprehensive Cancer Center, Sacramento, CA

  • University of California, San Francisco, CA

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • University of California, Los Angeles, Los Angeles, CA

  • Washington University School of Medicine, St. Louis, MO

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Knight Cancer Institute, Portland, OR

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved